Dumitru Cristinel Badiu1, Anca Zgura2, Claudia Mehedintu3, Bogdan Haineala4, Rodica Anghel5, Xenia Bacinschi5. 1. General Surgery Department, "Bagdasar Arseni" Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2. Department of Obstetrics-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; medicanca@gmail.com. 3. Department of Obstetrics and Gynecology, Malaxa Clinical Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 4. Department of Urology, "Fundeni" Clinical Institute, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 5. Department of Obstetrics-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Abstract
BACKGROUND/AIM: Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer. The association between PD-L1 expression and clinicopathological characteristics in lung cancer is still unclear. PATIENTS AND METHODS: This is a cross-sectional, observational study that evaluated a sample of 41 lung cancer patients diagnosed between March 2019 and December 2020. PD-L1 tumor expression is described as a percentage. RESULTS: Patients were diagnosed with non-microcellular lung cancer and aged 37 to 87 years. Most patients were diagnosed with adenocarcinoma. According to the analysis, the average age of patients with negative PD-L1 tumors was 65.6 years, and of those with positive PD-L1 tumors was 63.6 years. The average value of the tumor proportion score for males was 26.97%, and for females 25.55%. CONCLUSION: No correlation was found between PD-L1 tumor expression and the age and sex of patients.
BACKGROUND/AIM: Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer. The association between PD-L1 expression and clinicopathological characteristics in lung cancer is still unclear. PATIENTS AND METHODS: This is a cross-sectional, observational study that evaluated a sample of 41 lung cancer patients diagnosed between March 2019 and December 2020. PD-L1 tumor expression is described as a percentage. RESULTS: Patients were diagnosed with non-microcellular lung cancer and aged 37 to 87 years. Most patients were diagnosed with adenocarcinoma. According to the analysis, the average age of patients with negative PD-L1 tumors was 65.6 years, and of those with positive PD-L1 tumors was 63.6 years. The average value of the tumor proportion score for males was 26.97%, and for females 25.55%. CONCLUSION: No correlation was found between PD-L1 tumor expression and the age and sex of patients.
Authors: A Wang; H Y Wang; Y Liu; M C Zhao; H J Zhang; Z Y Lu; Y C Fang; X F Chen; G T Liu Journal: Eur J Surg Oncol Date: 2015-01-31 Impact factor: 4.424
Authors: Hilary A Robbins; Matthew Callister; Peter Sasieni; Samantha L Quaife; Li C Cheung; Paul Brennan; Hormuzd A Katki; Christine D Berg; David Baldwin; Mattias Johansson Journal: Lancet Respir Med Date: 2019-05-07 Impact factor: 30.700
Authors: A D'Incecco; M Andreozzi; V Ludovini; E Rossi; A Capodanno; L Landi; C Tibaldi; G Minuti; J Salvini; E Coppi; A Chella; G Fontanini; M E Filice; L Tornillo; R M Incensati; S Sani; L Crinò; L Terracciano; F Cappuzzo Journal: Br J Cancer Date: 2014-10-28 Impact factor: 7.640